Crohn's Disease Clinical Trials in Montreal, Quebec

10 recruitingMontreal, Quebec, Canada

Showing 110 of 10 trials

Recruiting
Phase 3

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Crohn's DiseaseUlcerative Colitis
Takeda240 enrolled98 locationsNCT05442567
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Crohn's Disease
Merck Sharp & Dohme LLC1,200 enrolled499 locationsNCT06430801
Recruiting
Phase 2

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

Crohn's Disease
Sanofi260 enrolled138 locationsNCT06637631
Recruiting
Phase 2

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease
Takeda268 enrolled194 locationsNCT06233461
Recruiting
Phase 3

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

Crohn's Disease
Janssen-Cilag Ltd.112 enrolled84 locationsNCT06408935
Recruiting
Phase 2

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

Crohn's Disease
AbbVie540 enrolled254 locationsNCT06548542
Recruiting
Phase 4

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Crohn's Disease
Takeda100 enrolled54 locationsNCT06045754
Recruiting

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

Crohn's Disease
Alimentiv Inc.300 enrolled25 locationsNCT06249555
Recruiting
Phase 3

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Crohn's Disease (CD)
Takeda120 enrolled96 locationsNCT04779320
Recruiting
Phase 3

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

Crohn's Disease
Takeda396 enrolled138 locationsNCT06227910